Operating Lease, Right-of-Use Asset of Tarsus Pharmaceuticals, Inc. from 31 Dec 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Tarsus Pharmaceuticals, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2019 to 31 Dec 2025.
  • Tarsus Pharmaceuticals, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 31 Dec 2025 was $10,080,000, a 1726% increase year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Tarsus Pharmaceuticals, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $10,080,000 +$9,528,000 +1726% 31 Dec 2025 10-K 23 Feb 2026 2025 FY
Q3 2025 $10,233,000 +$8,431,000 +468% 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $229,000 -$1,740,000 -88% 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $393,000 -$1,739,000 -82% 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $552,000 -$1,328,000 -71% 31 Dec 2024 10-K 23 Feb 2026 2025 FY
Q3 2024 $1,802,000 -$209,000 -10% 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 $1,969,000 -$168,000 -7.9% 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $2,132,000 +$1,592,000 +295% 31 Mar 2024 10-Q 08 May 2024 2024 Q1
Q4 2023 $1,880,000 +$1,305,000 +227% 31 Dec 2023 10-K 25 Feb 2025 2024 FY
Q3 2023 $2,011,000 +$1,315,000 +189% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $2,137,000 +$1,324,000 +163% 30 Jun 2023 10-Q 10 Aug 2023 2023 Q2
Q1 2023 $540,000 -$386,000 -42% 31 Mar 2023 10-Q 09 May 2023 2023 Q1
Q4 2022 $575,000 -$499,000 -46% 31 Dec 2022 10-K 27 Feb 2024 2023 FY
Q3 2022 $696,000 -$494,000 -42% 30 Sep 2022 10-Q 09 Nov 2022 2022 Q3
Q2 2022 $813,000 +$273,000 +51% 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
Q1 2022 $926,000 +$342,000 +59% 31 Mar 2022 10-Q 11 May 2022 2022 Q1
Q4 2021 $1,074,000 +$386,000 +56% 31 Dec 2021 10-K 17 Mar 2023 2022 FY
Q3 2021 $1,190,000 +$431,000 +57% 30 Sep 2021 10-Q 10 Nov 2021 2021 Q3
Q2 2021 $540,000 30 Jun 2021 10-Q 05 Aug 2021 2021 Q2
Q1 2021 $584,000 31 Mar 2021 10-Q 11 May 2021 2021 Q1
Q4 2020 $688,000 +$562,000 +446% 31 Dec 2020 10-K 14 Mar 2022 2021 FY
Q3 2020 $759,000 30 Sep 2020 10-Q 25 Nov 2020 2020 Q3
Q4 2019 $126,000 31 Dec 2019 10-K 31 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.